The drug, Kisunla, made by Eli Lilly, is the latest in a new class of treatments that could modestly slow cognitive decline in initial stages of the disease but also carry safety risks.
Category: Eli Lilly and Company
-
Advisory Panel of Experts Endorses F.D.A. Approval of New Alzheimer’s Drug
The modest benefits of the treatment, donanemab, made by Eli Lilly, outweigh the risks, the panel concluded unanimously.
-
U.S. Scrutiny of Chinese Company Could Disrupt U.S. Supply Chain for Key Drugs
Lawmakers raising national security concerns and seeking to disconnect a major Chinese firm from U.S. pharmaceutical interests have rattled the biotech industry. The firm is deeply involved in development and manufacturing of crucial therapies for cancer, cystic fibrosis, H.I.V. and other illnesses.
-
F.D.A. Delays Action on Closely Watched Alzheimer’s Drug
Eli Lilly’s donanemab was expected to be approved this month, but the agency has decided to convene a panel of independent experts to evaluate the drug’s safety and efficacy.
-
6 Reasons That It’s Hard to Get Your Wegovy and Other Weight-Loss Prescriptions
An array of obstacles make it difficult for patients to obtain Wegovy or Zepbound. Finding Wegovy is “like winning the lottery,” one nurse practitioner said.
-
How Much Do Ozempic and Wegovy Cost? Not What You Think.
Drug companies are making billions from a new class of in-demand weight-loss treatments. But the prices are not what they seem.
-
In China, the Police Came for the Consultants. Now the C.E.O.s Are Alarmed.
Foreign businesses, a top Chinese official said in March, “are not foreigners, but family.” Then came a crackdown on firms with foreign ties.
-
Eli Lilly Trial Finds Alzheimer’s Drug Can Slow Progress of Disease
Donanemab is not a cure and comes with significant side effects, but patients had longer periods of independent living while on the drug.
-
California’s Plan for Cheaper Insulin Collides With Big Pharma’s Price Cuts
The state awarded a $50 million contract to produce less costly treatments, but moves by major suppliers might undercut the initiative before any new product emerges.
-
Sanofi Plans to Cut the Price of Insulin
The company is the third of the three major insulin manufacturers that dominate the U.S. market to announce such a move this month.
-
Novo Nordisk Says It Will Slash the Price of Insulin
The company’s decision follows a similar move by its rival, Eli Lilly, this month.
-
Eli Lilly Says It Will Cut the Price of Insulin
The company said it would cap the monthly out-of-pocket cost of the diabetes drug at $35.